🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

25 results for “SANGAMO” Clear

  1. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  2. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  3. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  4. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  5. Plerixafor

    SANGAMO THERAPEUTICS, INC

    Sickle Cell Disease

    phase 2 mab completed

    1 trial

  6. SB-318

    SANGAMO THERAPEUTICS, INC

    MPS I

    phase 2 mab terminated

    1 trial

  7. SB-509

    SANGAMO THERAPEUTICS, INC

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials

  8. SB-509

    SANGAMO THERAPEUTICS, INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  9. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 2 gene therapy completed

    2 trials

  10. SB-728mR-T

    SANGAMO THERAPEUTICS, INC

    Human Immunodeficiency Virus (HIV)

    phase 2 gene therapy completed

    1 trial

  11. SB-913

    SANGAMO THERAPEUTICS, INC

    Mucopolysaccharidosis II

    phase 2 mab terminated

    1 trial

  12. ST-400 Investigational product

    SANGAMO THERAPEUTICS, INC

    Transfusion Dependent Beta-thalassemia

    phase 2 gene therapy completed

    1 trial

  13. ST-503

    SANGAMO THERAPEUTICS, INC

    Chronic Neuropathic Pain

    phase 2 gene therapy active

    1 trial

  14. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  15. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  16. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease

    phase 2 mab completed

    1 trial

  17. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 2 mab active

    1 trial

  18. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

  19. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  20. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  21. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV Infection

    phase 1 gene therapy completed

    1 trial

  22. SB-728mR-HSPC Infusion 3 days following busulfan conditioning

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 gene therapy active

    1 trial

  23. SB-FIX

    SANGAMO THERAPEUTICS, INC

    Hemophilia B

    phase 1 mab terminated

    1 trial

  24. ZFN modified T cells

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources